Enveda Raised $311 Million to Make New Pills From Nature
Enveda has raised $311 million in a Series E, a late round of startup funding, at a $2 billion valuation. The round was led by Catalio Capital Management, with Iconiq participating. The financing was reported on Sept. 23, 2026. TechCrunch
That $2 billion value is twice what the company was worth 12 months ago. Enveda is a clinical-stage biotech startup, which means it is testing drugs in people but has no approved drug yet. Yahoo Finance It was founded in 2019 by Viswa Colluru, who earlier worked at Recursion Pharmaceuticals before starting Enveda.
Enveda uses AI to look for new drugs in plants and microbes, tiny living things. The basic idea is old. Nearly half of all pill medicines start from a molecule first found in nature, according to the company. Enveda The hard part has always been search. Nature makes a huge number of chemicals, like a vast library with no catalog, and finding a useful one and turning it into a pill that can be made at scale is slow.
Enveda is now testing several AI-found drugs in human trials, including one for severe skin conditions. A separate drug is meant to help people keep weight off after stopping GLP-1s, the widely used weight-loss drugs. On Aug. 18, 2026, the company reported positive Phase 1 results, the first safety tests in people, for ENV-308, described as the "first pill designed from the chemistry of exercise." Enveda
The broader context here is simple. Finding drugs with AI is easy to claim and hard to prove. Computers can suggest and rank candidates very fast. That speed means little until the candidates pass safety tests and show effects in people. Enveda stands out to specialists because it has moved past computer-only work into several human programs. That step is where many similar platforms stall.
Looking at what this means for the company, money both enables and limits. The $311 million lets Enveda run several human trials at once. It also gives time to improve its discovery system while waiting for trial results. Investors doubling the value in a year are paying for progress in the clinic, not only for the AI platform. The risk is unchanged. Early success does not predict later success, and skin, weight maintenance and other uses each have different regulatory and business paths.
In my view, the choice of drugs is practical. A severe skin program gives a clear result to measure and a path to distinct data. A weight program next to GLP-1s tackles a problem doctors and patients already know, keeping benefit after stopping. ENV-308 points to a third path, turning normal body processes into a daily pill. If any one of these shows lasting benefit in people, the search engine behind them becomes much easier to value. Until then, the story is money, trials and steady pace. The long arc stays hopeful. Better search of natural chemistry should widen the set of drug ideas, if they are judged by human results.
